Physician profile
Randi M Wright
NPI 1730609439
$2,370.36
in general payments reported to CMS, 2019-2025
27 companies · $543 in 2025
The $543 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $513 · 2023: $539 · 2024: $520 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.97 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $671.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $448.08 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $179.41 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $161.02 | 2022-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $120.39 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $87.34 | 2022-2025 | |
| Astellas Pharma US INC | $86.48 | 2022-2023 | Veozah |
| Sumitomo Pharma America, INC. | $84.01 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $77.27 | 2024 | Rexulti |
| Abbott Laboratories | $69.46 | 2023 | Mitraclip |
| Currax Pharmaceuticals LLC | $66.40 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Pfizer INC. | $35.03 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.18 | 2022 | |
| Axsome Therapeutics, INC. | $31.40 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $30.52 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $20.83 | 2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.00 | 2022 | |
| Almatica Pharma LLC | $18.92 | 2024 | Loreev Xr |
| Krystal Biotech INC | $16.66 | 2025 | Vyjuvek |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2021 | |
| Lundbeck LLC | $15.81 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $15.22 | 2022 | |
| Phadia US INC. | $14.16 | 2023 | Immunocap |
| Sanofi Pasteur INC. | $14.00 | 2022 | |
| Esperion Therapeutics, INC. | $12.82 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.72 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.